PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-19.90%
Both companies show declining cash positions (-19.90% vs AVXL's -11.03%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-19.90%
Cash + STI yoy ≥ 1.5x AVXL's -11.03%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.69%
≥ 1.5x AVXL's -11.10%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
6.10%
Below half AVXL's -9.88%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both AVXL and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.84%
1.25-1.5x AVXL's 4.19%. Bruce Berkowitz checks if expansions surpass competitor's pace but remain justified.
No Data
No Data available this quarter, please select a different quarter.
-18.44%
≥ 1.5x AVXL's -9.51%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
65.60%
Above 1.5x AVXL's 0.29%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-100.00%
Less than half of AVXL's 3.67%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
≥ 1.5x AVXL's -0.29%. David Dodd sees stronger subscription/prepayment demand.
-13.55%
Less than half of AVXL's 37.97%. David Dodd sees fewer expansions in other current obligations.
-8.01%
Less than half of AVXL's 1.11%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.01%
Less than half of AVXL's 1.11%. David Dodd sees far fewer liability expansions relative to competitor.
7.31%
Higher Common Stock (Book Value) Growth compared to AVXL's zero value, indicating worse performance.
-7.62%
≥ 1.5x AVXL's -2.41%. David Dodd sees higher yoy retained profits than competitor.
-130.04%
Above 1.5x AVXL's -50.00%. Michael Burry sees a significant jump in intangible or market-based gains. Scrutinize risk of reversal.
No Data
No Data available this quarter, please select a different quarter.
-45.22%
≥ 1.5x AVXL's -11.89%. David Dodd sees stronger capital base growth than competitor.
-18.44%
≥ 1.5x AVXL's -9.51%. David Dodd sees faster overall balance sheet growth than competitor.
-100.00%
Both AVXL and the company show zero Total Investments Growth.
-100.00%
Less than half of AVXL's 3.69%. David Dodd sees less overall debt expansion vs. competitor.
19.60%
Above 1.5x AVXL's 11.35%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.